Pharmanutra S.p.a. · MIL:PHN
Pharmanutra — Q3 2024 Earnings Presentation
25 slides from Pharmanutra's earnings presentation, Nov 11, 2024
Slide 1: Q3 2024 Financial Results
Q3_2024 FINANCIAL RESULTS November 11th, 2024
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Highlights 2024
HIGHLIGHTS 2024 @PHARMANUTRA uw
Slide 4: Highlights Q3 2024
HIGHLIGHTS Q3 2024 4 • The results as of September 30, 2024, confirm, once again, a solid trend of organic growth in revenue and EBITDA, exceeding expectations, with increases of approximately 17% and 27%, respectively, compared to the same period of the previous year. • Revenue performance for the
Slide 5: Highlights Q3 2024
HIGHLIGHTS Q3 2024 5 The Net Financial Position as of September 30, 2024, is positive (net cash) at €0.5 million, compared to the negative balance of €2.6 million as of December 31, 2023. • Completion of the merger by incorporation of Alesco and Junia Pharma into Pharmanutra. • Agreement signed wi
Slide 6: Economic and Financial Data
ECONOMIC AND Z FINANCIAL DATA @PHARMANUTRA
Slide 7: Highlights Q3 2024
7 HIGHLIGHTS Q3 2024 NET REVENUES € 83,5 M + 17% Net Sales Revenues organic increase of 17% compared (€ 71,5 M IN Q3 2023) to Q3 2023. 29% EBITDA margin on net revenues. EBITDA margin on EBITDA € 24,2 M net revenues related to the recurring business 33% +27% (+27% COMPARED TO € 19 M IN Q3 (30,5%
Slide 8: Net Revenues
8 NET REVENUES Net revenues at 30.09.2024 accounted for € 83,4 million, recording a 17% increase compared to the previous year. Revenues on foreign markets recorded a growth of 33% while revenues on domestic market increased by 13%. Akern’s net revenues accounted for € 4,1 million (+13%), about 5% o
Slide 9: Net Revenues by Trademark and Area of Business
9 NET REVENUES BY TRADEMARK AND AREA OF BUSINESS Revenues breakdown by Trademark and Area of Business Incidence % €/000 2024 2023 Δ% 2024 2023 Sideral 57.756 50.317 14,8% 69% 70% Cetilar 8.074 7.125 13,3% 10% 10% Apportal 8.312 6.104 36,2% 10% 9% Ultramag 1.194 776 53,8% 1% 1% Other 1.839 1.743 5,5%
Slide 10: Profit and Loss
10 PROFIT AND LOSS PHN GROUP PROFIT AND LOSS (€/000) 30/09/2024 30/09/2023 REVENUES A) REVENUES 84.497 72.190 The contribution of revenues from new projects is still marginal (about Net Revenues 83.470 71.434 €1,7 m of which € 1 million from China). Other revenues 1.027 756 B) OPERATING EXPENSES 60.
Slide 11: Net Financial Position
11 NET FINANCIAL POSITION NFP The significative amount of cash generated by the operating activities (€ 14 million) allowed the Group to came back to a positive cash position net of outflows related to Capex (€ 2,5M), share buybacks (€ 551K) and dividend distribution (€ 8,2M).
Slide 12: Quarter Results vs Last Year
12 QUARTER RESULTS VS LAST YEAR
Slide 13: Stock and Consensus Performance
STOCK AND CONSENSUS PERFORMANCE
Slide 14: Consensus Compared to Actual Result - Revenues
14 CONSENSUS COMPARED TO ACTUAL RESULT - REVENUES Consensus Q4 2024 Source: Intermonte
Slide 15: Consensus Compared to Actual Result - EBITDA
15 CONSENSUS COMPARED TO ACTUAL RESULT - EBITDA Consensus Q4 2024 Source: Intermonte
Slide 16: DPS vs Stock Performance
DPS VS STOCK PERFORMANCE 75,40 €0,90 €0,75 €0,60 €0,45 €0,30 2017 2018 2019 2020 2021 2022 @PHARMANUTRA -@-Dividend per share -®-Stock Performance (31/12) 2023
Slide 17: Market
MARKET @PHARMANUTRA
Slide 18: Pharmanutra Is a Relevant Player in the Italian Nutraceutical Market
18 PHARMANUTRA IS A RELEVANT PLAYER IN THE ITALIAN NUTRACEUTICAL MARKET TOP 10 COMPANIES IN THE NUTRACEUTIC MARKET 2021 2022 2023 COMPANIES: 716 Source IQVIA_Turnover of the top 10 pharmacy companies (millions of €) PRODUCTS: 7.012 Evaluation on the Nutraceutical Market_excluding Cetilar
Slide 19: Two Pharmanutra Products in the Top 20 Dietary Supplements Sold in Italy
19 TWO PHARMANUTRA PRODUCTS IN THE TOP20 DIETARY SUPPLEMENTS SOLD IN ITALY Since November 2019 is N°1 Dietary Supplement sold in Italy Source: New Line Ricerche di Mercato
Slide 20: Trend Sell In/Sell Out
20 TREND SELL IN/SELL OUT Sell Out: Source IQVIA Source IQVIA
Slide 21: Wide International Network
21 WIDE INTERNATIONAL NETWORK CROSS BORDER PHARMANUTRA U.S. Corp. E-COMMERCE PHARMANUTRA PHARMANUTRA ESPANA SpA In addition to direct subsidiaries PharmaNutra operates in 87 countries with 58 partners, carefully selected among the best international pharmaceutical and nutraceutical companies.
Slide 22: China Sales Development
22 CHINA SALES DEVELOPMENT The trend of sales in the Chinese market highlights significant growth opportunities. In this context, an additional platform for Apportal® online sales has recently been activated.
Slide 23: Outlook 2024
OUTLOOK 2024 ran @PHARMANUTRA
Slide 24: Outlook 2024
24 OUTLOOK 2024 The strong organic growth that has characterized the Group's performance over the first nine months of 2024, despite a highly challenging environment, is expected to continue in the fourth quarter, enabling results that exceed both expectations and the Group's targets. The develo
Slide 25: Q@PHARMANUTRA
te © eS Q@PHARMANUTRA | L